Delivery Order SPE2DB22D9207-SPE2DB25FH4YP
Award Date
4/9/25
Potential Completion Date
4/30/25
Potential Value
$16K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,623.52 contract is for the delivery of KADCYLA 160 MG vials, a cancer treatment medication, with a completion date of May 24, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $12,728.46 and has an ultimate completion date of April 29, 2025. It is for the delivery of 160 mg vials of the drug Kadcyla. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. also holds a larger $499,999,999 Indefinite Delivery Contract...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, a prescription oncology drug, with a completion date of August 13, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a potential value of $15,358.74 and is for the delivery of the pharmaceutical product KADCYLA 100 MG VIALS. The delivery order is part of a larger indefinite delivery contract between DMS Pharmaceutical Group and DLA that has a potential value up to $5 million through December 2025. This contract vehicle allows DLA to procure a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $5,119.56 contract is for the delivery of Kadcyla 100mg vials, a specialty oncology medication. The order is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA to provide a comprehensive range of...
This is a $13,790.74 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of KADCYLA 160 MG VIALS, a specialized pharmaceutical product, with a period of performance through March 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of KADCYLA 160 MG vials, with a ceiling value of $41,039.20 and a period of performance through July 30, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $15,358.74 and covers the delivery of Kadcyla 100 mg vials, a specialty oncology medication, with a completion date of August 15, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued...
This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through July 19, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with DLA under the SPE2DB program, which allows the agency...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, with a period of performance through August 28, 2024. DMS Pharmaceutical Group holds a large single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued up to $499,999,999, which allows the...